Tumors with deregulated gangliosides synthesis can be responsive to treatment with UGCG inhibitors, such miglustat and eliglustat, which are already used in the clinic for the treatment of children with Gaucher disease [15, 70, 74]. This evidence concerns the gene UGCG and Gaucher disease.